Study title:
Orenstein SR et al. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: An open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Clin Ther. April 1, 2005, 472-83Orenstein SR et al. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: An open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Clin Ther. April 1, 2005, 472-83
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Digestive System Diseases [C06]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: SIMETICONE |
ATC code: A02DA01 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|